Non-Hodgkins Lymphoma Clinical Trial
Official title:
Phase II Trial of Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in the Treatment of Patients With Relapsed/Refractory Intermediate Grade B-Cell Lymphoma
In this Multicenter trial, we will evaluate the feasibility, toxicity, and efficacy of treatment with 90Y Zevalin following a short course of salvage chemotherapy in patients with relapsed/refractory intermediate grade B-cell non-Hodgkin's lymphoma.
Upon determination of eligibility, patients will receive:
- Ifosfamide + Carboplatin + Etoposide + Rituximab
Patients showing no response to this combination regimen will receive 90Y Zevalin after two
cycles or when progression is clearly documented. In responding patients, four cycles will
be administered, followed by 90Y Zevalin.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04240704 -
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL
|
Phase 1 | |
| Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
| Recruiting |
NCT00807196 -
Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
| Completed |
NCT00764829 -
Blood Samples to Evaluate Biomarkers of Donor Chimerism
|
N/A | |
| Completed |
NCT00726934 -
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
|
N/A | |
| Completed |
NCT01517581 -
Brown Fat Activity and White Fat Accumulation
|
N/A | |
| Terminated |
NCT01744912 -
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
|
Phase 1 | |
| Terminated |
NCT01500161 -
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
|
Phase 2 | |
| Active, not recruiting |
NCT03533283 -
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT00001379 -
Treatment and Natural History Study of Lymphomatoid Granulomatosis
|
Phase 2 | |
| Completed |
NCT00574730 -
CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma
|
N/A | |
| Completed |
NCT00901225 -
Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant
|
Phase 2 | |
| Terminated |
NCT01598025 -
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor
|
N/A | |
| Terminated |
NCT01326728 -
Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation
|
||
| Completed |
NCT01290549 -
A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma
|
Phase 1 | |
| Completed |
NCT00837200 -
Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies
|
Phase 2 | |
| Completed |
NCT00807677 -
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
|
Phase 1 | |
| Terminated |
NCT00054834 -
Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma
|
Phase 1 | |
| Terminated |
NCT00003500 -
Antineoplaston Therapy in Treating Patients With Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma
|
Phase 2 | |
| Active, not recruiting |
NCT02099266 -
Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment
|
N/A |